Forecast: Antihypertensive Medicine Sales in Australia

The antihypertensive medicine sales in Australia have been displaying consistent growth. In 2023, sales stood at 6.5 USD per capita. From 2024 onwards, the forecasted data shows a steady increase, with values rising from 6.7 in 2024 to 7.7 USD per capita by 2028. This trend represents average year-on-year growths of 4.5% over the last two years and an estimated CAGR of 4.2% over the next five years, indicating a positive and sustained expansion in the market.

Future trends to watch for include advancements in antihypertensive medications, shifts in healthcare policies, and demographic changes such as an aging population, which may further drive market growth. Continuous monitoring would also be essential for any potential disruptive innovations or changes in medical guidelines affecting hypertensive treatment.